TP,Add_to_black_list,FP,candidate,ADJ,count_nct,is_mab,is_therapy,sentence,sents,_ids,link_to_ct_gov
,1,,mfolfox,FALSE,1,FALSE,FALSE,- The secondary endpoint is to assess disease local control and the response rate after short course radiotherapy concurrent with dose escalation infusion 5-fu followed by mFOLFOX and delayed surgery,{'- The secondary endpoint is to assess disease local control and the response rate after short course radiotherapy concurrent with dose escalation infusion 5-fu followed by mFOLFOX and delayed surgery'},{'NCT04370418'},NCT04370418
,1,,fosamprenavir/,FALSE,1,FALSE,FALSE,"A 12-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy of Fosamprenavir/Lexiva for Laryngopharyngeal Reflux (LPR).","{'A 12-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy of Fosamprenavir/Lexiva for Laryngopharyngeal Reflux (LPR).'}",{'NCT04383262'},NCT04383262
1,,,syn125,FALSE,1,FALSE,FALSE,A Phase 1 Dose Escalation Trial of SYN125 Single Agent and in Combination With Fixed Dose SYN004 in Patients With Advanced Colorectal and Head and Neck Cancer.,"{'A Phase 1 Dose Escalation Trial of SYN125 Single Agent and in Combination With Fixed Dose SYN004 in Patients With Advanced Colorectal and Head and Neck Cancer.', 'A Phase 1 Dose Escalation Trial of SYN125 Single Agent and in Combination With Fixed Dose SYN004 in Patients With Advanced Colorectal and Head and Neck Cancer'}",{'NCT04363242'},NCT04363242
1,,,syn004,FALSE,1,FALSE,FALSE,A Phase 1 Dose Escalation Trial of SYN125 Single Agent and in Combination With Fixed Dose SYN004 in Patients With Advanced Colorectal and Head and Neck Cancer.,"{'A Phase 1 Dose Escalation Trial of SYN125 Single Agent and in Combination With Fixed Dose SYN004 in Patients With Advanced Colorectal and Head and Neck Cancer.', 'A Phase 1 Dose Escalation Trial of SYN125 Single Agent and in Combination With Fixed Dose SYN004 in Patients With Advanced Colorectal and Head and Neck Cancer'}",{'NCT04363242'},NCT04363242
1,,,srf388,FALSE,1,FALSE,FALSE,A Phase 1 Study of SRF388 in Patients With Advanced Solid Tumors.,"{'A Phase 1 Study of SRF388 in Patients With Advanced Solid Tumors.', 'This is a Phase 1, open-label, first in human, monotherapy dose-escalation, safety study of SRF388, a monoclonal antibody that targets IL-27, in patients with solid tumors'}",{'NCT04374877'},NCT04374877
1,,,com902,FALSE,1,FALSE,FALSE,A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies.,"{'A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies.', 'Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM902 as monotherapy in subjects with advanced malignancies'}",{'NCT04354246'},NCT04354246
1,,,sotorasib,FALSE,1,FALSE,FALSE,"A Phase 1, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects of Chinese Descent With Advanced/Metastatic Solid Tumors With KRAS p.","{'A Phase 1, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects of Chinese Descent With Advanced/Metastatic Solid Tumors With KRAS p.'}",{'NCT04380753'},NCT04380753
1,,,oncr-177,FALSE,1,FALSE,FALSE,"A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors.","{'A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors.', 'ONCR-177-101 is a phase 1, open-label, multi-center, dose escalation and expansion study of ONCR-177, an oncolytic Herpes Simplex Virus for intratumoral injection, alone and in combination with PD-1 blockade in adult subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors.'}",{'NCT04348916'},NCT04348916
1,,,t3011,FALSE,1,FALSE,FALSE,"A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of T3011 in Advanced Cutaneous or Subcutaneous Malignancies.","{'A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of T3011 in Advanced Cutaneous or Subcutaneous Malignancies.', 'A phase 1, open-label, first-in-human study of T3011 monotherapy to evaluate the safety and tolerability of T3011 in patients with advanced cancers with cutaneous or subcutaneous tumor deposits who have progressed while receiving standard of care therapy or who will not benefit from such therapy'}",{'NCT04370587'},NCT04370587
1,,,bms-986315,FALSE,1,FALSE,FALSE,A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors.,"{'A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors.', 'Study of BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors'}",{'NCT04349267'},NCT04349267
,1,,18f ftc 146,FALSE,1,FALSE,FALSE,A Phase 2 Study of 18F FTC 146 PET/CT in Patients With Newly Diagnosed Osteosarcoma.,{'A Phase 2 Study of 18F FTC 146 PET/CT in Patients With Newly Diagnosed Osteosarcoma.'},{'NCT04365660'},NCT04365660
1,,,io-202,FALSE,1,FALSE,FALSE,A Phase I Study of IO-202 as Monotherapy and in Combination With Azacitidine in Relapsed/ Refractory AML With Monocytic Differentiation and in Relapsed/Refractory CMML.,"{'A Phase I Study of IO-202 as Monotherapy and in Combination With Azacitidine in Relapsed/ Refractory AML With Monocytic Differentiation and in Relapsed/Refractory CMML.', 'To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with relapsed or refractory monocytic AML and CMML in order to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D) and dose schedule as monotherapy and in combination with azacitidine (AZA)'}",{'NCT04372433'},NCT04372433
1,,,apg-115,FALSE,1,FALSE,FALSE,A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML.,{'A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML.'},{'NCT04358393'},NCT04358393
1,,,gemdoce,FALSE,1,FALSE,FALSE,A Phase II Trial for the Use of Intravesical Gemcitabine and Docetaxel (GEMDOCE) in the Treatment of BCG naïve Non-muscle Invasive Urothelial Carcinoma of the Bladder.,{'A Phase II Trial for the Use of Intravesical Gemcitabine and Docetaxel (GEMDOCE) in the Treatment of BCG naïve Non-muscle Invasive Urothelial Carcinoma of the Bladder.'},{'NCT04386746'},NCT04386746
1,,,ly01610（irinotecan hydrochloride,FALSE,1,FALSE,FALSE,A Phase IIa Study Evaluate the Efficacy and Safety of LY01610（Irinotecan Hydrochloride Liposome Injection） in Patients With Small Cell Lung Cancer.,{'A Phase IIa Study Evaluate the Efficacy and Safety of LY01610（Irinotecan Hydrochloride Liposome Injection） in Patients With Small Cell Lung Cancer.'},{'NCT04381910'},NCT04381910
,1,,camrelizumbab,FALSE,1,FALSE,FALSE,"A Randomized Trial of Comparison of MAPI+Camrelizumbab Verus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcomaies : an Open-label, Exploratory Study.","{'A Randomized Trial of Comparison of MAPI+Camrelizumbab Verus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcomaies : an Open-label, Exploratory Study.'}",{'NCT04351308'},NCT04351308
,1,,mapi,FALSE,1,FALSE,FALSE,"A Randomized Trial of Comparison of MAPI+Camrelizumbab Verus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcomaies : an Open-label, Exploratory Study.","{'A Randomized Trial of Comparison of MAPI+Camrelizumbab Verus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcomaies : an Open-label, Exploratory Study.'}",{'NCT04351308'},NCT04351308
,1,,lenvatnib,FALSE,1,FALSE,FALSE,"A Randomized, Open, Two-cohort Phase 2 Study of Toripalimab(PD1) Combined With Lenvatnib, or Gemox Chemotherapy Combined With Lenvatinib as First-line Therapy in Patients With Advanced or Unresectable Intrahepatic Cholangiocarcinoma.","{'A Randomized, Open, Two-cohort Phase 2 Study of Toripalimab(PD1) Combined With Lenvatnib, or Gemox Chemotherapy Combined With Lenvatinib as First-line Therapy in Patients With Advanced or Unresectable Intrahepatic Cholangiocarcinoma.'}",{'NCT04361331'},NCT04361331
1,,,hmpl-453 tartrate,FALSE,1,FALSE,FALSE,"A Single-arm, Multicenter, Open-label Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-453 Tartrate in Patients With Advanced Intrahepatic Cholangiocarcinoma With FGFR2 Fusion.","{'A Single-arm, Multicenter, Open-label Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-453 Tartrate in Patients With Advanced Intrahepatic Cholangiocarcinoma With FGFR2 Fusion.'}",{'NCT04353375'},NCT04353375
1,,,azithromycin,FALSE,3,FALSE,FALSE,"A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic.","{'A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic.', 'Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients:', 'Anecdotal data and some prospective results suggested a role of antimalarial drugs (chloroquine and hydroxychloroquine) in the treatment of this disease with best available data showing value of adding azithromycin.', 'Treatments have been administered to patients with COVID-19 in order to control viral infection, among them: Chloroquine (CQ) and Hydroxychloroquine (HCQ), Lopinavir/Ritonavir (Lop/r), Remdesivir, Favipavir, acting over bacterial co-infection Azithromycin (Azithro), or modifying the inflammatory response of the host (Tocilizumab).'}","{'NCT04359095', 'NCT04374903', 'NCT04369365'}",NCT04359095
,1,,afp,FALSE,1,FALSE,FALSE,A Study of AFP Specific T Cell Receptor Transduced T Cells Injection in Unresectable Hepatocellular Carcinoma.,{'A Study of AFP Specific T Cell Receptor Transduced T Cells Injection in Unresectable Hepatocellular Carcinoma.'},{'NCT04368182'},NCT04368182
1,,,tegio,FALSE,1,FALSE,FALSE,"A Study on the Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer.","{'A Study on the Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer.', 'This is a prospective, single-center, single-arm, open-label clinical study, aiming at evaluating the efficacy and safety of camrelizumab for injection, apatinib mesylate and tegio for first-line refractory patients with advanced gastric cancer'}",{'NCT04345783'},NCT04345783
1,,,c-tcr055,FALSE,1,FALSE,FALSE,A study that aimed to assess the safety and anti-tumor activity of C-TCR055 injection in unresectable HCC patients,{'A study that aimed to assess the safety and anti-tumor activity of C-TCR055 injection in unresectable HCC patients'},{'NCT04368182'},NCT04368182
1,,,ab-16b5,FALSE,1,FALSE,FALSE,All recruited patients will receive AB-16B5 at a dose of 12 mg/kg once weekly combined with docetaxel at a dose of 75 mg/m2 once every 3 weeks,"{'All recruited patients will receive AB-16B5 at a dose of 12 mg/kg once weekly combined with docetaxel at a dose of 75 mg/m2 once every 3 weeks', 'A Phase II Study of AB-16B5 Combined With Docetaxel in Previously Treated Subjects With Metastatic Non-Small Cell Lung Cancer.'}",{'NCT04364620'},NCT04364620
1,,,almonertinib,FALSE,1,FALSE,FALSE,Almonertinib Versus Paclitaxel Plus Carboplatin as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Pulmonary Adenosquamous Carcinoma:,{'Almonertinib Versus Paclitaxel Plus Carboplatin as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Pulmonary Adenosquamous Carcinoma:'},{'NCT04354961'},NCT04354961
1,,,nerofe,FALSE,1,FALSE,FALSE,"An Open-Label Phase 1b Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).","{'An Open-Label Phase 1b Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).', 'This is an open-label Phase 1b study of NEROFE following a traditional 3+3 design to assess safety and to determine the Recommended Phase 2 Dose (RP2D) of NEROFE in patients with MDS or AML.', 'IV NEROFE will be administered three times per week on alternate days.'}",{'NCT04365179'},NCT04365179
1,,,fasturtec,FALSE,1,FALSE,FALSE,"An Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin¿s Lymphoma and Acute Leukemia.","{'An Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin¿s Lymphoma and Acute Leukemia.'}",{'NCT04349306'},NCT04349306
1,,,sctil210,FALSE,1,FALSE,FALSE,"An Open-lable,Single-arm,Single-dose Escalation and Multiple-dose Expansion Clinical Study of Cell Therapy to Observe and Evaluate the Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma.","{'An Open-lable,Single-arm,Single-dose Escalation and Multiple-dose Expansion Clinical Study of Cell Therapy to Observe and Evaluate the Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma.'}",{'NCT04357509'},NCT04357509
,1,,pld,FALSE,2,FALSE,FALSE,"Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer(APPROVE): a Randomized, Controlled, Open-label, Phase 2 Trial.","{'Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer(APPROVE): a Randomized, Controlled, Open-label, Phase 2 Trial.', 'This study sought to assess the efficacy and safety of the combination therapy of apatinib and PLD, clarifying whether combination therapy could improve the outcomes of patients with platinum-resistant recurrent ovarian cancer', 'Therefore, we designed this phase II trial with PLD and 5-Fu to compare irinotecan monotherapy in the second-line treatment'}","{'NCT04358341', 'NCT04348032'}",NCT04358341
,1,,abi,FALSE,1,FALSE,FALSE,"Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy","{'Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy'}",{'NCT04363164'},NCT04363164
,1,,enza,FALSE,1,FALSE,FALSE,"Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy","{'Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy'}",{'NCT04363164'},NCT04363164
1,,,alvocade,FALSE,1,FALSE,FALSE,"Bortezomib considered the standard of care for treating multiple myeloma patients, we aimed to assess the safety and efficacy of newly approved drug (Alvocade ®) in Iraq, in newly diagnosed patients","{'Bortezomib considered the standard of care for treating multiple myeloma patients, we aimed to assess the safety and efficacy of newly approved drug (Alvocade ®) in Iraq, in newly diagnosed patients'}",{'NCT04348006'},NCT04348006
,1,,camrelizumab（shr-1210,FALSE,1,TRUE,FALSE,Camrelizumab（SHR-1210） in this study is a Chinese anti-PD-1 monoclonal antibody for injection which has been approved for melanoma and Hepatocellular carcinoma.,{'Camrelizumab（SHR-1210） in this study is a Chinese anti-PD-1 monoclonal antibody for injection which has been approved for melanoma and Hepatocellular carcinoma.'},{'NCT04367025'},NCT04367025
,1,,car-t,FALSE,2,FALSE,FALSE,Clinical Study of CEA-Targeted CAR-T Therapy in Patients With Relapsed and Refractory CEA+ Cancer.,"{'Clinical Study of CEA-Targeted CAR-T Therapy in Patients With Relapsed and Refractory CEA+ Cancer.', 'At the same time, combined with four generations of CAR-T cells and PD1 monoclonal antibody, PD1 / PDL1 signal pathway was blocked, anti-tumor effect of CAR-T was improved, and immune response and long-term remission rate of DLBCL were improved'}","{'NCT04348643', 'NCT04381741'}",NCT04348643
,1,,pyridine,FALSE,1,FALSE,FALSE,"Compared with imatinib, it introduced trifluoromethyl, substituted pyridine ring for benzene ring, and kept the direction of amide bond, which made the inhibitory effect of flumatinib on common kinase mutations significantly better than that of imatinib.","{'Compared with imatinib, it introduced trifluoromethyl, substituted pyridine ring for benzene ring, and kept the direction of amide bond, which made the inhibitory effect of flumatinib on common kinase mutations significantly better than that of imatinib.'}",{'NCT04375683'},NCT04375683
,,1,hcq,FALSE,3,FALSE,FALSE,COVID19-HOPE trial will randomize patients to 2 arms: HCQ/AZ (Arm A) and HCQ/SIR (Arm B).,"{'COVID19-HOPE trial will randomize patients to 2 arms: HCQ/AZ (Arm A) and HCQ/SIR (Arm B).', 'This study is evaluating the safety and efficacy of combining the study drug LY3214996 with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer', 'Treatments have been administered to patients with COVID-19 in order to control viral infection, among them: Chloroquine (CQ) and Hydroxychloroquine (HCQ), Lopinavir/Ritonavir (Lop/r), Remdesivir, Favipavir, acting over bacterial co-infection Azithromycin (Azithro), or modifying the inflammatory response of the host (Tocilizumab).'}","{'NCT04359095', 'NCT04386057', 'NCT04374903'}",NCT04359095
,,1,sir,FALSE,1,FALSE,FALSE,COVID19-HOPE trial will randomize patients to 2 arms: HCQ/AZ (Arm A) and HCQ/SIR (Arm B).,{'COVID19-HOPE trial will randomize patients to 2 arms: HCQ/AZ (Arm A) and HCQ/SIR (Arm B).'},{'NCT04374903'},NCT04374903
,,1,az,FALSE,1,FALSE,FALSE,COVID19-HOPE trial will randomize patients to 2 arms: HCQ/AZ (Arm A) and HCQ/SIR (Arm B).,{'COVID19-HOPE trial will randomize patients to 2 arms: HCQ/AZ (Arm A) and HCQ/SIR (Arm B).'},{'NCT04374903'},NCT04374903
,1,,t-dxd,FALSE,1,FALSE,FALSE,"DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or durvalumab in HER2-positive advanced/metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma patients.","{'DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or durvalumab in HER2-positive advanced/metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma patients.', 'T-DXd in combination with cytotoxic chemotherapy or immune checkpoint inhibitor administered to HER2-positive gastric/GEJ cancer patients who have not received prior treatment for advanced/metastatic disease will show preliminary evidence of anti-tumour activity and the potential to become a therapeutic option for this patient population', 'Study hypotheses: Combination of T-DXd with cytotoxic chemotherapy and/or durvalumab administered to subjects at the recommended phase 2 dose will show manageable safety and tolerability and preliminary anti-tumor efficacy so as to permit further clinical testing.', 'A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2 Overexpressing Gastric Cancer (DESTINY-Gastric03).'}",{'NCT04379596'},NCT04379596
,,1,sodium,FALSE,1,FALSE,FALSE,Effect of Sunitinib Treatment on Tissue Sodium Accumulation in Patients With Renal Cancer: a Pilot Study.,"{'Effect of Sunitinib Treatment on Tissue Sodium Accumulation in Patients With Renal Cancer: a Pilot Study.', 'Here, it is investigated how sunitinib, a tyrosine kinase-inhibitor targeting vascular endothelial growth factor receptors, might influence sodium homeostasis in the skin and if this is related to a well-described treatment side-effect of sunitinib, hypertension'}",{'NCT04368546'},NCT04368546
,1,,camrelizumabin,FALSE,1,TRUE,FALSE,Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody (Camrelizumabin) the Locally Advanced Adenocarcinoma of Stomach or Gastroesophageal Junction.,{'Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody (Camrelizumabin) the Locally Advanced Adenocarcinoma of Stomach or Gastroesophageal Junction.'},{'NCT04367025'},NCT04367025
,1,,erapa,FALSE,1,FALSE,FALSE,eRapa (encapsulated rapamycin) will be investigated for secondary prevention in patients with diagnosed non-muscle invasive bladder cancer (NMIBC) through a phase II double-blind randomized controlled trial of long-term (one year) prevention with eRapa versus placebo.,"{'eRapa (encapsulated rapamycin) will be investigated for secondary prevention in patients with diagnosed non-muscle invasive bladder cancer (NMIBC) through a phase II double-blind randomized controlled trial of long-term (one year) prevention with eRapa versus placebo.', 'Phase II Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention.'}",{'NCT04375813'},NCT04375813
1,,,w_pro1,FALSE,1,FALSE,FALSE,"First-in-human, Dose Titration and Expansion Trial to Evaluate Safety, Immunogenicity and Preliminary Efficacy of W_pro1 in Patients With Metastatic Castration Resistant Prostate Cancer and W_pro1 in Combination With Cemiplimab and/or Goserelin Acetate in Patients With High-risk, Localized Prostate Cancer.","{'First-in-human, Dose Titration and Expansion Trial to Evaluate Safety, Immunogenicity and Preliminary Efficacy of W_pro1 in Patients With Metastatic Castration Resistant Prostate Cancer and W_pro1 in Combination With Cemiplimab and/or Goserelin Acetate in Patients With High-risk, Localized Prostate Cancer.'}",{'NCT04382898'},NCT04382898
,1,,azithro,FALSE,1,FALSE,FALSE,"Four interventions have been defined: I1 HCQ, I2 HCQ plus Lop/r, I3 HCQ plus Azithro and I4 standard treatment.","{'Four interventions have been defined: I1 HCQ, I2 HCQ plus Lop/r, I3 HCQ plus Azithro and I4 standard treatment.', 'Treatments have been administered to patients with COVID-19 in order to control viral infection, among them: Chloroquine (CQ) and Hydroxychloroquine (HCQ), Lopinavir/Ritonavir (Lop/r), Remdesivir, Favipavir, acting over bacterial co-infection Azithromycin (Azithro), or modifying the inflammatory response of the host (Tocilizumab).'}",{'NCT04359095'},NCT04359095
,,1,gs,FALSE,1,FALSE,FALSE,"Gemcitabine plus S-1 (GS) will be administered initially, and then CA 19-9 will be evaluated.","{'Gemcitabine plus S-1 (GS) will be administered initially, and then CA 19-9 will be evaluated.'}",{'NCT04377048'},NCT04377048
,,1,ala,FALSE,1,FALSE,FALSE,"However, with administration of ALA, which has been shown to be selectively concentrated in neoplastic cells, it is reasonable to expect responses in the target lesion(s) with relative sparing of nearby normal structures.","{'However, with administration of ALA, which has been shown to be selectively concentrated in neoplastic cells, it is reasonable to expect responses in the target lesion(s) with relative sparing of nearby normal structures.'}",{'NCT04381806'},NCT04381806
1,,,tranexamic acid,FALSE,2,FALSE,FALSE,"In order to reduce bleeding, we're planning to use tranexamic acid in the operations.","{""In order to reduce bleeding, we're planning to use tranexamic acid in the operations."", 'Effect of Tranexamic Acid Infusion to Reduce Intraoperative Blood Loss in Large Meningioma: A Prospective Randomized Double-blind Control Study.', 'Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer.', 'Tranexamic acid has been used in surgery for more than 30 years.', 'In this experiment, we will observe the efficacy of tranexamic acid in cytoreductive surgery for ovarian cancer, find the best dosage which can reach the desired effect, and the possible side-effect', 'In neurosurgical setting, a large sample size trials of tranexamic acid (TXA) has been limited to TBI and SAH.'}","{'NCT04360629', 'NCT04386642'}",NCT04360629
1,,,itacinib,FALSE,1,FALSE,FALSE,"Itacinib is a protein inhibitor of the tyrosine kinase, JAK1, which is believed to enable cancer cells to metastasise to other parts of the body","{'Itacinib is a protein inhibitor of the tyrosine kinase, JAK1, which is believed to enable cancer cells to metastasise to other parts of the body'}",{'NCT04358185'},NCT04358185
1,,,bupivacaine,FALSE,2,FALSE,FALSE,"Lidocaine is the most commonly used anesthetic in MMS, but bupivacaine has been shown in other surgical specialties to be an effective adjuvant to reduce post-operative pain and opioid use when injected locally in the immediate postoperative period.","{'Lidocaine is the most commonly used anesthetic in MMS, but bupivacaine has been shown in other surgical specialties to be an effective adjuvant to reduce post-operative pain and opioid use when injected locally in the immediate postoperative period.', 'Use of Liposomal Bupivacaine (Exparel) In Expedited Recovery Following Lower Extremity Amputation.', 'The investigators plan a single-blinded prospective, randomized, controlled trial to determine if post-operative wound infiltration of bupivacaine versus normal saline improves post-operative pain and decreases need for post-operative pain medications including both narcotic and nonnarcotic analgesics', 'Randomized Trial of Bupivacaine as Adjuvant for Post-operative Pain in Mohs Micrographic Surgery.', 'Bupivacaine has also been shown to reduce intra-operative pain during MMS.', 'The purpose of this investigator-initiated study is to assess the use of liposomal bupivacaine in major extremity amputation and its effects on post-operative opioid narcotic use, length of stay, and in-hospital costs.', 'Application of liposomal bupivacaine in extremity amputation is not well described.', 'Liposomal bupivacaine is an encapsulated, injectable amide anesthetic intended for use in long-acting local anesthesia.', 'Patients will receive targeted injections of liposomal bupivacaine during their procedure.'}","{'NCT04362566', 'NCT04360421'}",NCT04362566
,,1,amide,FALSE,1,FALSE,FALSE,"Liposomal bupivacaine is an encapsulated, injectable amide anesthetic intended for use in long-acting local anesthesia.","{'Liposomal bupivacaine is an encapsulated, injectable amide anesthetic intended for use in long-acting local anesthesia.'}",{'NCT04360421'},NCT04360421
,,1,hyperpolarized,FALSE,1,FALSE,FALSE,Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) as a Diagnostic and Response Monitoring Imaging Tool in Advanced Prostate Cancer.,{'Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) as a Diagnostic and Response Monitoring Imaging Tool in Advanced Prostate Cancer.'},{'NCT04346225'},NCT04346225
1,,,fluorescein sodium,FALSE,1,FALSE,FALSE,Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560.,{'Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560.'},{'NCT04351373'},NCT04351373
,1,,oncr-177-101,FALSE,1,FALSE,FALSE,"ONCR-177-101 is a phase 1, open-label, multi-center, dose escalation and expansion study of ONCR-177, an oncolytic Herpes Simplex Virus for intratumoral injection, alone and in combination with PD-1 blockade in adult subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors.","{'ONCR-177-101 is a phase 1, open-label, multi-center, dose escalation and expansion study of ONCR-177, an oncolytic Herpes Simplex Virus for intratumoral injection, alone and in combination with PD-1 blockade in adult subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors.'}",{'NCT04348916'},NCT04348916
,,1,sars-cov-2,FALSE,1,FALSE,FALSE,"One possible explanation is that the immune system of elderly people, might be exhausted by chronic stimulation associated with comorbidities and more susceptible to this Sars-CoV-2 effect.","{'One possible explanation is that the immune system of elderly people, might be exhausted by chronic stimulation associated with comorbidities and more susceptible to this Sars-CoV-2 effect.'}",{'NCT04374526'},NCT04374526
1,,,rtx-240,FALSE,1,FALSE,FALSE,"Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors","{'Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors', 'Phase 1/2 Study of RTX-240 Monotherapy.'}",{'NCT04372706'},NCT04372706
,,1,ep,FALSE,1,FALSE,FALSE,Our aim in this study was to evaluate the efficacy and safety of etoposide combined with cisplatin or carboplatin (EC/EP) chemotherapy regimens followed by toripalimab combined with anlotinib for maintenance in extensive small cell lung cancer(ES-SCLC),{'Our aim in this study was to evaluate the efficacy and safety of etoposide combined with cisplatin or carboplatin (EC/EP) chemotherapy regimens followed by toripalimab combined with anlotinib for maintenance in extensive small cell lung cancer(ES-SCLC)'},{'NCT04363255'},NCT04363255
,,1,ec,FALSE,1,FALSE,FALSE,Our aim in this study was to evaluate the efficacy and safety of etoposide combined with cisplatin or carboplatin (EC/EP) chemotherapy regimens followed by toripalimab combined with anlotinib for maintenance in extensive small cell lung cancer(ES-SCLC),{'Our aim in this study was to evaluate the efficacy and safety of etoposide combined with cisplatin or carboplatin (EC/EP) chemotherapy regimens followed by toripalimab combined with anlotinib for maintenance in extensive small cell lung cancer(ES-SCLC)'},{'NCT04363255'},NCT04363255
,,1,mms,FALSE,1,FALSE,FALSE,Pain after MMS peaks on the day of surgery and slowly decreases thereafter.,{'Pain after MMS peaks on the day of surgery and slowly decreases thereafter.'},{'NCT04362566'},NCT04362566
1,,,bupivicaine,FALSE,1,FALSE,FALSE,Patients receiving liposomal bupivicaine will be compared to similarly matched subjects who received standard anesthesia regimens without liposomal bupivicaine.,"{'Patients receiving liposomal bupivicaine will be compared to similarly matched subjects who received standard anesthesia regimens without liposomal bupivicaine.', 'We hypothesize that liposomal bupivicaine used during major amputation decreases opioid use, hospital stay, and in-hospital costs'}",{'NCT04360421'},NCT04360421
,1,,amvac,FALSE,1,FALSE,FALSE,Pembrolizumab and aMVAC Chemotherapy as Neoadjuvant Therapy in Non-Urothelial Histology Muscle-Invasive Bladder Cancer: A Pilot Trial.,{'Pembrolizumab and aMVAC Chemotherapy as Neoadjuvant Therapy in Non-Urothelial Histology Muscle-Invasive Bladder Cancer: A Pilot Trial.'},{'NCT04383743'},NCT04383743
,1,,gastric acid,FALSE,1,FALSE,FALSE,"Pepsin, detected in the airway of these patients and now known to cause laryngeal inflammation and promote disease independent of gastric acid, is a key therapeutic target.","{'Pepsin, detected in the airway of these patients and now known to cause laryngeal inflammation and promote disease independent of gastric acid, is a key therapeutic target.'}",{'NCT04383262'},NCT04383262
,,1,covid-19,FALSE,2,FALSE,FALSE,Phase 1/2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 Infection.,"{'Phase 1/2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 Infection.', 'Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment.'}","{'NCT04379518', 'NCT04363216'}",NCT04379518
1,,,ifn-alpha,FALSE,1,FALSE,FALSE,Phase 1/2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 Infection.,{'Phase 1/2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 Infection.'},{'NCT04379518'},NCT04379518
1,,,ino-5401,FALSE,1,FALSE,FALSE,Phase 1b Study of INO-5401 Alone or INO-5401 in Combination With INO-9012 Followed by Electroporation in Adults With BRCA1 or BRCA2 Mutations.,{'Phase 1b Study of INO-5401 Alone or INO-5401 in Combination With INO-9012 Followed by Electroporation in Adults With BRCA1 or BRCA2 Mutations.'},{'NCT04367675'},NCT04367675
1,,,msb0254,FALSE,1,FALSE,FALSE,Phase I Clinical Trial to Evaluate the Safety and Tolerability and Pharmacokinetics of MSB0254 Injection in Patients With Advanced Solid Tumors.,"{'Phase I Clinical Trial to Evaluate the Safety and Tolerability and Pharmacokinetics of MSB0254 Injection in Patients With Advanced Solid Tumors.', 'This study was an open, multi-dose dose escalation phase I clinical study to evaluate the safety, tolerability and PK characteristics of MSB0254 in patients with locally advanced or metastatic solid tumors, and to preliminarily measure its anti-tumor efficacy'}",{'NCT04381325'},NCT04381325
,1,,short-fox,FALSE,1,FALSE,FALSE,Phase II Trial of Organ Preservation Program Using Short-Course Radiation and FOLFOXIRI for Rectal Cancer (SHORT-FOX).,{'Phase II Trial of Organ Preservation Program Using Short-Course Radiation and FOLFOXIRI for Rectal Cancer (SHORT-FOX).'},{'NCT04380337'},NCT04380337
,1,,duavee®,FALSE,1,FALSE,FALSE,Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms at Increased Risk for Breast Cancer.,"{'Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms at Increased Risk for Breast Cancer.', 'Pilot study to test feasibility of 6 months of Duavee® vs wait-list control in post-menopausal women symptomatic for hot flashes'}",{'NCT04379024'},NCT04379024
,1,,c-13,FALSE,1,FALSE,FALSE,"Preliminary pre-clinical and clinical data demonstrates the ability of HP C-13 pyruvate/metabolic MR imaging to detect high-grade prostate cancer, including cancer with neuroendocrine differentiation, as well as provide early evidence of metabolic response and resistance following application of systemic therapies for the treatment of advanced prostate cancer patients.","{'Preliminary pre-clinical and clinical data demonstrates the ability of HP C-13 pyruvate/metabolic MR imaging to detect high-grade prostate cancer, including cancer with neuroendocrine differentiation, as well as provide early evidence of metabolic response and resistance following application of systemic therapies for the treatment of advanced prostate cancer patients.'}",{'NCT04346225'},NCT04346225
,1,,napoli,FALSE,1,FALSE,FALSE,Randomized Phase II Study of NaliCap (Irinotecan Liposome/Capecitabine) Compared to NAPOLI (Irinotecan Liposome/5-fluorouracil/Leucovorin) in Gemcitabine-pretreated Advanced Pancreatic Cancer.,"{'Randomized Phase II Study of NaliCap (Irinotecan Liposome/Capecitabine) Compared to NAPOLI (Irinotecan Liposome/5-fluorouracil/Leucovorin) in Gemcitabine-pretreated Advanced Pancreatic Cancer.', 'This is an open label, randomized phase 2 study of NaliCap (irinotecan liposome/Capecitabine) compared to NAPOLI (irinotecan liposome/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer patients'}",{'NCT04371224'},NCT04371224
,1,,nalicap,FALSE,1,FALSE,FALSE,Randomized Phase II Study of NaliCap (Irinotecan Liposome/Capecitabine) Compared to NAPOLI (Irinotecan Liposome/5-fluorouracil/Leucovorin) in Gemcitabine-pretreated Advanced Pancreatic Cancer.,"{'Randomized Phase II Study of NaliCap (Irinotecan Liposome/Capecitabine) Compared to NAPOLI (Irinotecan Liposome/5-fluorouracil/Leucovorin) in Gemcitabine-pretreated Advanced Pancreatic Cancer.', 'This is an open label, randomized phase 2 study of NaliCap (irinotecan liposome/Capecitabine) compared to NAPOLI (irinotecan liposome/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer patients'}",{'NCT04371224'},NCT04371224
,1,,double stranded ribonucleic acid,FALSE,1,FALSE,FALSE,Rintatolimod is double stranded ribonucleic acid (RNA) designed to mimic viral infection by stimulating immune pathways that are normally activated during viral infection.,{'Rintatolimod is double stranded ribonucleic acid (RNA) designed to mimic viral infection by stimulating immune pathways that are normally activated during viral infection.'},{'NCT04379518'},NCT04379518
1,,,flumatinib,FALSE,1,FALSE,FALSE,Subjects aged 60 years or older are received flumatinib and dose-adjusted VDCP or prednisone regimen.,"{'Subjects aged 60 years or older are received flumatinib and dose-adjusted VDCP or prednisone regimen.', 'Compared with imatinib, it introduced trifluoromethyl, substituted pyridine ring for benzene ring, and kept the direction of amide bond, which made the inhibitory effect of flumatinib on common kinase mutations significantly better than that of imatinib.', 'Flumatinib is the first approved second generation TKI in China and a derivative of imatinib.', 'A Study of Flumatinib Combined With Chemotherapy in the Treatment of Ph Positive Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring.', 'In addition, compared with the second-generation TKI recommended in the first line of current guidelines, the incidence of quality of life related adverse reactions of flumatinib is lower, and no specific adverse reactions of the second-generation TKI have been reported.', 'Subjects younger than 60 years are received flumatinib and hyper-CVAD regimen.'}",{'NCT04375683'},NCT04375683
,1,,vdcp,FALSE,1,FALSE,FALSE,Subjects aged 60 years or older are received flumatinib and dose-adjusted VDCP or prednisone regimen.,{'Subjects aged 60 years or older are received flumatinib and dose-adjusted VDCP or prednisone regimen.'},{'NCT04375683'},NCT04375683
,1,,ferumoxytol,FALSE,1,FALSE,FALSE,"Subjects will undergo a single MRI study: a pre-contrast, single breath hold image followed by sterile placement of a temporary urethral catheter for instillation of a 50mL solution containing Gadobutrol (4 mM) plus ferumoxytol (5 mM) and then a second, post-contrast image.","{'Subjects will undergo a single MRI study: a pre-contrast, single breath hold image followed by sterile placement of a temporary urethral catheter for instillation of a 50mL solution containing Gadobutrol (4 mM) plus ferumoxytol (5 mM) and then a second, post-contrast image.'}",{'NCT04369560'},NCT04369560
,1,,gadobutrol,FALSE,1,FALSE,FALSE,"Subjects will undergo a single MRI study: a pre-contrast, single breath hold image followed by sterile placement of a temporary urethral catheter for instillation of a 50mL solution containing Gadobutrol (4 mM) plus ferumoxytol (5 mM) and then a second, post-contrast image.","{'Subjects will undergo a single MRI study: a pre-contrast, single breath hold image followed by sterile placement of a temporary urethral catheter for instillation of a 50mL solution containing Gadobutrol (4 mM) plus ferumoxytol (5 mM) and then a second, post-contrast image.'}",{'NCT04369560'},NCT04369560
1,,,dm1,FALSE,1,FALSE,FALSE,"T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called DM1.","{'T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called DM1.'}",{'NCT04351230'},NCT04351230
,1,,corticosteroid,FALSE,1,FALSE,FALSE,The aim of this study is to evaluate the omission of corticosteroid doses as a pre-medication in cancer treatment after the second week of treatment with taxane in a curative setting,{'The aim of this study is to evaluate the omission of corticosteroid doses as a pre-medication in cancer treatment after the second week of treatment with taxane in a curative setting'},{'NCT04350229'},NCT04350229
1,,,oseltamivir,FALSE,1,FALSE,FALSE,The evidence for using sirolimus for influenza is emphasized by a RCT that showed reduction of mechanical ventilation time by 50% (7 days on sirolimus arm vs 15 days on oseltamivir/steroids arm).,{'The evidence for using sirolimus for influenza is emphasized by a RCT that showed reduction of mechanical ventilation time by 50% (7 days on sirolimus arm vs 15 days on oseltamivir/steroids arm).'},{'NCT04374903'},NCT04374903
1,,,ibuprofen,FALSE,1,FALSE,FALSE,"The most common post-operative analgesics include acetaminophen, ibuprofen and narcotics.","{'The most common post-operative analgesics include acetaminophen, ibuprofen and narcotics.'}",{'NCT04362566'},NCT04362566
1,,,zkab001,FALSE,2,FALSE,FALSE,The patients with high-grade osteosarcoma who had previously received surgery and completed adjuvant chemotherapy will be randomly assigned to ZKAB001 group (trial group) or placebo group (control group) according to 1:,"{'The patients with high-grade osteosarcoma who had previously received surgery and completed adjuvant chemotherapy will be randomly assigned to ZKAB001 group (trial group) or placebo group (control group) according to 1:', 'To evaluate the safety and efficacy of recombinant anti-PD-L1 monoclonal antibody injection (ZKAB001) combined with carboplatin and etoposide in the treatment of extensive-stage small cell lung cancer', '1. The purpose is to evaluate the efficacy and safety of ZKAB001 in maintenance therapy after adjuvant chemotherapy in patients with high-grade osteosarcoma', 'Phase Ib Study of Recombinant Anti-PD-L1 Monoclonal Antibody Injection (ZKAB001) Combined With Carboplatin and Etoposide in the Treatment of Extensive Small Cell Lung Cancer.', 'A Randomized, Double-blind, Placebo-controlled, Multicenter，Phase III Clinical Study of Recombinant Anti-PD-L1 Monoclonal Antibody (ZKAB001) for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy.'}","{'NCT04359550', 'NCT04346914'}",NCT04359550
,1,,xeloxiri,FALSE,1,FALSE,FALSE,"The phase I/II study was designed to evaluate if the regimen of Irinotecan, Oxaliplatin, Capecitabine (XELOXIRI) and Bevacizumab is a superior first-line option for patients with metastatic colorectal cancer(mCRC) in terms of safety and efficacy","{'The phase I/II study was designed to evaluate if the regimen of Irinotecan, Oxaliplatin, Capecitabine (XELOXIRI) and Bevacizumab is a superior first-line option for patients with metastatic colorectal cancer(mCRC) in terms of safety and efficacy', 'A Phase I/II Study of Irinotecan, Oxaliplatin, Capecitabine (XELOXIRI) and Bevacizumab as a First-line Therapy for Patients With Metastatic Colorectal Cancer.'}",{'NCT04380103'},NCT04380103
1,,,ng101m,FALSE,1,FALSE,FALSE,The purpose of this clinical trial is to evaluate the addition of NG101m adjuvant therapy to standard of care treatment of glioblastoma multiforme.,"{'The purpose of this clinical trial is to evaluate the addition of NG101m adjuvant therapy to standard of care treatment of glioblastoma multiforme.', 'All subjects will receive NG101m capsules along with the standard treatment of temozolomide and radiation', 'A Multi-Center Pilot/Phase I and Phase II Clinical Trial of NG101m Adjuvant Therapy in Newly Diagnosed Glioblastoma Patients.'}",{'NCT04373785'},NCT04373785
1,,,18f ftc-146,FALSE,1,FALSE,FALSE,"The purpose of this research is to evaluate the study drug, 18F FTC-146, as a positron emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate tumor status in patients newly diagnosed with osteosarcoma (""bone cancer"")","{'The purpose of this research is to evaluate the study drug, 18F FTC-146, as a positron emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate tumor status in patients newly diagnosed with osteosarcoma (""bone cancer"")'}",{'NCT04365660'},NCT04365660
,1,,capa,FALSE,1,FALSE,FALSE,"The purpose of this study is to evaluate the efficacy and safety of camrelizumab, apatinib, pegaspargase (CAPA) and as an intruction immunotherapy with radiotherapy as first-line treatment in patients with de novo stage IE/IIE extranodal natural killer/T-cell lymphoma, nasal type","{'The purpose of this study is to evaluate the efficacy and safety of camrelizumab, apatinib, pegaspargase (CAPA) and as an intruction immunotherapy with radiotherapy as first-line treatment in patients with de novo stage IE/IIE extranodal natural killer/T-cell lymphoma, nasal type'}",{'NCT04366128'},NCT04366128
1,,,5-fluorouacil,FALSE,1,FALSE,FALSE,"The purpose of this study is to test the investigational agent, Pembrolizumab, in combination with SOC radiation and Capecitabine (or 5-Fluorouacil) in treatment of patients with mismatch repair deficient locally advanced rectal cancer","{'The purpose of this study is to test the investigational agent, Pembrolizumab, in combination with SOC radiation and Capecitabine (or 5-Fluorouacil) in treatment of patients with mismatch repair deficient locally advanced rectal cancer'}",{'NCT04357587'},NCT04357587
1,,,lexiva,FALSE,1,FALSE,FALSE,"The Specific Aim of this project is to perform a 12-week randomized, double-blind, placebo-controlled clinical trial to assess the efficacy of fosamprenavir/Lexiva for LPR.","{'The Specific Aim of this project is to perform a 12-week randomized, double-blind, placebo-controlled clinical trial to assess the efficacy of fosamprenavir/Lexiva for LPR.', 'Lexiva will be used at the FDA approved, manufacturers recommended dose for HIV for 12 weeks in medically refractory patients with clinically diagnosed moderate/severe LPR and combined multi-channel intraluminal impedance - pH (MII-pH) confirmed laryngeal reflux events.', 'Routine clinical outcome measures for LPR (Reflux Symptom Index and Reflux Finding Score) will be documented pre- and post-treatment with Lexiva (n = 52) and placebo (n = 52).', 'A 12-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy of Fosamprenavir/Lexiva for Laryngopharyngeal Reflux (LPR).'}",{'NCT04383262'},NCT04383262
1,,,fosamprenavir,FALSE,1,FALSE,FALSE,"The Specific Aim of this project is to perform a 12-week randomized, double-blind, placebo-controlled clinical trial to assess the efficacy of fosamprenavir/Lexiva for LPR.","{'The Specific Aim of this project is to perform a 12-week randomized, double-blind, placebo-controlled clinical trial to assess the efficacy of fosamprenavir/Lexiva for LPR.'}",{'NCT04383262'},NCT04383262
1,,,sh003,FALSE,1,FALSE,FALSE,"The study is designed as a single Group, Dose Elevating trial which evaluates safety to confirm the final maximum tolerated dose by the combination of oral administration of SH003 to docetaxel administered patients.","{'The study is designed as a single Group, Dose Elevating trial which evaluates safety to confirm the final maximum tolerated dose by the combination of oral administration of SH003 to docetaxel administered patients.', 'Phase I Study to Evaluate the Maximum Tolerated Dose of the Combination of SH003 and Docetaxel in Patients With Solid Cancer.'}",{'NCT04360317'},NCT04360317
1,,,yh001,FALSE,1,FALSE,FALSE,"The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of YH001 when administered in combination with Toripalimab to subjects with advanced solid tumors","{'The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of YH001 when administered in combination with Toripalimab to subjects with advanced solid tumors', 'This is an open-label, dose-escalation study of YH001 administered intravenously (IV) in combination with Toripalimab.', 'A First-in-human (FIH), Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors.'}",{'NCT04357756'},NCT04357756
1,,,povidone-iodine,FALSE,1,FALSE,FALSE,The Study of Extended Thymectomy and Pleural Reductive Surgery (PRS) With Povidone-iodine Pleural Lavage in Patients With Stage IVA Thymic Malignancies.,{'The Study of Extended Thymectomy and Pleural Reductive Surgery (PRS) With Povidone-iodine Pleural Lavage in Patients With Stage IVA Thymic Malignancies.'},{'NCT04371458'},NCT04371458
,1,,dhea,FALSE,1,FALSE,FALSE,"The study uses multiple agents in combination with personalized doses of recombinant human growth hormone (somatropin), metformin, and DHEA, in a similar manner to how the combination treatment was applied in the earlier TRIIM trial at Stanford, which demonstrated strong statistical significance for the primary efficacy endpoints that will be evaluated in TRIIM-X. Somatropin is approved by the FDA for adult growth hormone deficiency and its use in the study is guided by prior safety data established for that use and also based on safety data available on its prior use in the TRIIM trial and in clinical practice in healthy elderly individuals.","{'The study uses multiple agents in combination with personalized doses of recombinant human growth hormone (somatropin), metformin, and DHEA, in a similar manner to how the combination treatment was applied in the earlier TRIIM trial at Stanford, which demonstrated strong statistical significance for the primary efficacy endpoints that will be evaluated in TRIIM-X. Somatropin is approved by the FDA for adult growth hormone deficiency and its use in the study is guided by prior safety data established for that use and also based on safety data available on its prior use in the TRIIM trial and in clinical practice in healthy elderly individuals.'}",{'NCT04375657'},NCT04375657
1,,,somatropin,FALSE,1,FALSE,FALSE,"The study uses multiple agents in combination with personalized doses of recombinant human growth hormone (somatropin), metformin, and DHEA, in a similar manner to how the combination treatment was applied in the earlier TRIIM trial at Stanford, which demonstrated strong statistical significance for the primary efficacy endpoints that will be evaluated in TRIIM-X. Somatropin is approved by the FDA for adult growth hormone deficiency and its use in the study is guided by prior safety data established for that use and also based on safety data available on its prior use in the TRIIM trial and in clinical practice in healthy elderly individuals.","{'The study uses multiple agents in combination with personalized doses of recombinant human growth hormone (somatropin), metformin, and DHEA, in a similar manner to how the combination treatment was applied in the earlier TRIIM trial at Stanford, which demonstrated strong statistical significance for the primary efficacy endpoints that will be evaluated in TRIIM-X. Somatropin is approved by the FDA for adult growth hormone deficiency and its use in the study is guided by prior safety data established for that use and also based on safety data available on its prior use in the TRIIM trial and in clinical practice in healthy elderly individuals.'}",{'NCT04375657'},NCT04375657
1,,,ak117,FALSE,1,FALSE,FALSE,"This is a first-in-human, Phase 1, multicenter, open label, single arm, integrated 3-part dose escalation and dose expansion study designed to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK117 administered intravenously to adult subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas","{'This is a first-in-human, Phase 1, multicenter, open label, single arm, integrated 3-part dose escalation and dose expansion study designed to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK117 administered intravenously to adult subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas', 'A Phase 1, Multicenter, Open Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 in Subjects With Relapsed/Refractory Advanced or Metastatic Solid Tumors or Lymphomas.'}",{'NCT04349969'},NCT04349969
1,,,ly01610,FALSE,1,FALSE,FALSE,"This is a Multicenter, Non-randomized, Open Label, Multiple Dose, Multiple administration, Phase IIa Clinical Study Evaluating the Efficacy and Safety of LY01610 in Patients with Extensive-stage Small Cell Lung Cancer that Progressed after first-line Antitumor Therapy","{'This is a Multicenter, Non-randomized, Open Label, Multiple Dose, Multiple administration, Phase IIa Clinical Study Evaluating the Efficacy and Safety of LY01610 in Patients with Extensive-stage Small Cell Lung Cancer that Progressed after first-line Antitumor Therapy'}",{'NCT04381910'},NCT04381910
1,,,tq-b3525,FALSE,1,FALSE,FALSE,"This is a open-label, multicenter phase Ib study to evaluate safety and efficacy of TQ-B3525 tablets combined with fulvestrant injection in subjects with HR-positive, HER2-negative and PIK3CA mutation advanced breast cancer","{'This is a open-label, multicenter phase Ib study to evaluate safety and efficacy of TQ-B3525 tablets combined with fulvestrant injection in subjects with HR-positive, HER2-negative and PIK3CA mutation advanced breast cancer', 'A Phase Ib, Single-arm, Open-label Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer.'}",{'NCT04355520'},NCT04355520
1,,,177lu-dota-tate,FALSE,1,FALSE,FALSE,This is a phase I study of 177Lu-DOTA-TATE in combination with the PARP-inhibitor olaparib for treatment of patients with somatostatin receptor positive tumours detected by 68Ga-DOTA-TATE/TOC PET.,"{'This is a phase I study of 177Lu-DOTA-TATE in combination with the PARP-inhibitor olaparib for treatment of patients with somatostatin receptor positive tumours detected by 68Ga-DOTA-TATE/TOC PET.', 'Phase I Trial With 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours.'}",{'NCT04375267'},NCT04375267
1,,,68ga-dota-tate,FALSE,1,FALSE,FALSE,This is a phase I study of 177Lu-DOTA-TATE in combination with the PARP-inhibitor olaparib for treatment of patients with somatostatin receptor positive tumours detected by 68Ga-DOTA-TATE/TOC PET.,{'This is a phase I study of 177Lu-DOTA-TATE in combination with the PARP-inhibitor olaparib for treatment of patients with somatostatin receptor positive tumours detected by 68Ga-DOTA-TATE/TOC PET.'},{'NCT04375267'},NCT04375267
1,,,hmpl-453,FALSE,1,FALSE,FALSE,"This is a phase II, single arm, multicenter and open-label study to evaluate the efficacy, safety and pharmacokinetic of HMPL-453 tartrate in patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusion","{'This is a phase II, single arm, multicenter and open-label study to evaluate the efficacy, safety and pharmacokinetic of HMPL-453 tartrate in patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusion'}",{'NCT04353375'},NCT04353375
,1,,tartrate,FALSE,1,FALSE,FALSE,"This is a phase II, single arm, multicenter and open-label study to evaluate the efficacy, safety and pharmacokinetic of HMPL-453 tartrate in patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusion","{'This is a phase II, single arm, multicenter and open-label study to evaluate the efficacy, safety and pharmacokinetic of HMPL-453 tartrate in patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusion'}",{'NCT04353375'},NCT04353375
1,,,tqb3558,FALSE,1,FALSE,FALSE,"This is a study to evaluate the maximum tolerated dose (MTD) , occurrence of all adverse events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor effect of TQB3558 tablets in Chinese adult patients with advanced solid tumors .","{'This is a study to evaluate the maximum tolerated dose (MTD) , occurrence of all adverse events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor effect of TQB3558 tablets in Chinese adult patients with advanced solid tumors .', 'A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3558 Tablets.', 'Phase Ia: dose escalation period, to evaluate the safety and tolerability of TQB3558 tablets, determine MTD; Phase Ib: effectiveness exploration period, to expand the safe and effective dose group, recommend appropriate dosage and method for subsequent clinical research'}",{'NCT04367844'},NCT04367844
1,,,ibi939,FALSE,1,FALSE,FALSE,"This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of IBI939 in subjects with advanced malignancies","{'This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of IBI939 in subjects with advanced malignancies'}",{'NCT04353830'},NCT04353830
1,,,yh002,FALSE,1,FALSE,FALSE,"This is an open-label, dose-escalation study of the study drug YH002.","{'This is an open-label, dose-escalation study of the study drug YH002.', 'The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of YH002 in patients with advanced solid Malignancies', 'A First-in-Human (FIH), Multicenter, Open-Label, Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YH002 in Subjects With Advanced Solid Malignancies.'}",{'NCT04353102'},NCT04353102
,1,,flag,FALSE,1,FALSE,FALSE,This phase 2 clinical trial investigates the effectiveness of cytokine-induced memory-like natural killer (CIML NK) cells in combination with FLAG chemotherapy as a treatment for refractory or relapsed AML.,"{'This phase 2 clinical trial investigates the effectiveness of cytokine-induced memory-like natural killer (CIML NK) cells in combination with FLAG chemotherapy as a treatment for refractory or relapsed AML.', ""This phase 2 study uses FLAG chemotherapy to lower leukemic burden and suppress the recipient's immune system to provide an optimal environment for CIML NK cell expansion and anti-leukemic activity""}",{'NCT04354025'},NCT04354025
1,,,cb-5339,FALSE,1,FALSE,FALSE,This phase I trial studies the side effects and best dose of CB-5339 in treating patients with solid tumors that has spread to other places in the body (advanced) or lymphomas.,"{'This phase I trial studies the side effects and best dose of CB-5339 in treating patients with solid tumors that has spread to other places in the body (advanced) or lymphomas.', 'A Phase I Trial of the P97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas.', 'CB-5339 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth'}",{'NCT04372641'},NCT04372641
,,1,her2,FALSE,2,FALSE,FALSE,This phase II trial studies how well abemaciclib with or without T-DM1 works for the treatment of HER2-positive breast cancer that has spread to other places in the body (metastatic).,"{'This phase II trial studies how well abemaciclib with or without T-DM1 works for the treatment of HER2-positive breast cancer that has spread to other places in the body (metastatic).', 'A Phase III,Randomized,Multicenter,Double-blind Clinical Trail to Evaluate the Efficacy,Safety and Immunogenicity of the Combination of TQ-B211 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First-line Treatment in Patients With HER2-positive MBC.'}","{'NCT04351230', 'NCT04385563'}",NCT04351230
1,,,6mhp,FALSE,1,FALSE,FALSE,This study evaluates whether it is safe to administer a peptide vaccine made of 6MHP and a mutated neoantigen peptide (BRAF585-614-V600E) combined with adjuvants.,{'This study evaluates whether it is safe to administer a peptide vaccine made of 6MHP and a mutated neoantigen peptide (BRAF585-614-V600E) combined with adjuvants.'},{'NCT04364230'},NCT04364230
1,,,ef-009,FALSE,1,FALSE,FALSE,"This study is a multi center, open-label, dose escalation, Phase I/IIa study of EF-009 in up to 30 patients with borderline resectable and unresectable pancreatic cancer","{'This study is a multi center, open-label, dose escalation, Phase I/IIa study of EF-009 in up to 30 patients with borderline resectable and unresectable pancreatic cancer', 'A Phase I/IIa Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety and Efficacy Profile of EF-009 in Patients With Pancreatic Cancer.'}",{'NCT04381130'},NCT04381130
1,,,lp-108,FALSE,1,FALSE,FALSE,"This study is a multi-center, open-label, single-arm phase I clinical study of LP-108.","{'This study is a multi-center, open-label, single-arm phase I clinical study of LP-108.', 'A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the Oral BCL-2 Inhibitor LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma.', 'After the RP2Ds are determined, additional patients will be enrolled in the expansion phase to further evaluation the safety, PK and preliminary efficacy of LP-108, each therapy can enroll 12-20 subjects'}",{'NCT04356846'},NCT04356846
1,,,uv1,FALSE,1,FALSE,FALSE,This study will explore the Efficacy and Safety of UV1 administered with GM-CSF in combination with nivolumab and ipilimumab,"{'This study will explore the Efficacy and Safety of UV1 administered with GM-CSF in combination with nivolumab and ipilimumab', 'Efficacy and Safety of UV1 Vaccination in Combination With Nivolumab and Ipilimumab as First Line Treatment of Patients With Unresectable or Metastatic Melanoma (INITIUM Study).'}",{'NCT04382664'},NCT04382664
1,,,relacorilant,FALSE,1,FALSE,FALSE,This study will investigate the safety and efficacy of Relacorilant in combination with Pembrolizumab for Patients with Adrenocortical Carcinoma with Excess Glucocorticoid Production,"{'This study will investigate the safety and efficacy of Relacorilant in combination with Pembrolizumab for Patients with Adrenocortical Carcinoma with Excess Glucocorticoid Production', 'A Phase 1b, Open-Label Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production.'}",{'NCT04373265'},NCT04373265
1,,,b002,FALSE,1,FALSE,FALSE,To assess the safety and tolerability characteristics of B002 in patients with HER2-positive recurrent or metastatic breast cancer.,"{'To assess the safety and tolerability characteristics of B002 in patients with HER2-positive recurrent or metastatic breast cancer.', 'Experimental Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of B002 in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer.'}",{'NCT04382352'},NCT04382352
1,,,pentoxifylline,FALSE,1,FALSE,FALSE,"To date, there are few specific treatments for these severe radio-induced fibrosis except the antifibrotic combinaison Pentoxifylline/Vitamin E with inconsistent result.","{'To date, there are few specific treatments for these severe radio-induced fibrosis except the antifibrotic combinaison Pentoxifylline/Vitamin E with inconsistent result.'}",{'NCT04356209'},NCT04356209
,1,,bacillus-calmette-guerin,FALSE,1,FALSE,FALSE,To evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscular invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease with carcinoma in situ (CIS) with or without Ta/T1 papillary disease,{'To evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscular invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease with carcinoma in situ (CIS) with or without Ta/T1 papillary disease'},{'NCT04387461'},NCT04387461
1,,,tq-b211,FALSE,1,FALSE,FALSE,"To evaluate the efficacy,safety and immunogenicity of TQ-B211 plus docetaxel versus Herceptin® plus docetaxel in Patients with HER2-positive metastatic breast cancer.","{'To evaluate the efficacy,safety and immunogenicity of TQ-B211 plus docetaxel versus Herceptin® plus docetaxel in Patients with HER2-positive metastatic breast cancer.', 'A Phase III,Randomized,Multicenter,Double-blind Clinical Trail to Evaluate the Efficacy,Safety and Immunogenicity of the Combination of TQ-B211 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First-line Treatment in Patients With HER2-positive MBC.'}",{'NCT04385563'},NCT04385563
,1,,providone-iodine,FALSE,1,FALSE,FALSE,To evaluate whether intraoperative pleural lavage with providone-iodine following complete resection and pleural reductive surgery for stage IVA thymoma reduces recurrent rates compared to surgery without providone-iodine lavage,{'To evaluate whether intraoperative pleural lavage with providone-iodine following complete resection and pleural reductive surgery for stage IVA thymoma reduces recurrent rates compared to surgery without providone-iodine lavage'},{'NCT04371458'},NCT04371458
,1,,txa,FALSE,1,FALSE,FALSE,"To prove the benefit of TXA for an attenuation of blood loss in brain tumor patients, research with a larger sample size is required.","{'To prove the benefit of TXA for an attenuation of blood loss in brain tumor patients, research with a larger sample size is required.', 'This prospective, randomized double-blind controlled study will be conducted to evaluate the effect of TXA in reducing blood loss and blood transfusion in patients with intracranial meningiomas, diameter > 5 cm in at least 2 dimensions from the latest radiographic findings', 'The evidence of TXA in brain tumor was scarce.', 'A few case reports support the role of TXA in brain tumor patients with significant intraoperative bleeding and difficult achieving hemostasis.', 'In neurosurgical setting, a large sample size trials of tranexamic acid (TXA) has been limited to TBI and SAH.'}",{'NCT04386642'},NCT04386642
,1,,lop/r,FALSE,1,FALSE,FALSE,"Treatments have been administered to patients with COVID-19 in order to control viral infection, among them: Chloroquine (CQ) and Hydroxychloroquine (HCQ), Lopinavir/Ritonavir (Lop/r), Remdesivir, Favipavir, acting over bacterial co-infection Azithromycin (Azithro), or modifying the inflammatory response of the host (Tocilizumab).","{'Treatments have been administered to patients with COVID-19 in order to control viral infection, among them: Chloroquine (CQ) and Hydroxychloroquine (HCQ), Lopinavir/Ritonavir (Lop/r), Remdesivir, Favipavir, acting over bacterial co-infection Azithromycin (Azithro), or modifying the inflammatory response of the host (Tocilizumab).'}",{'NCT04359095'},NCT04359095
1,,,lopinavir/ritonavir,FALSE,1,FALSE,FALSE,"Treatments have been administered to patients with COVID-19 in order to control viral infection, among them: Chloroquine (CQ) and Hydroxychloroquine (HCQ), Lopinavir/Ritonavir (Lop/r), Remdesivir, Favipavir, acting over bacterial co-infection Azithromycin (Azithro), or modifying the inflammatory response of the host (Tocilizumab).","{'Treatments have been administered to patients with COVID-19 in order to control viral infection, among them: Chloroquine (CQ) and Hydroxychloroquine (HCQ), Lopinavir/Ritonavir (Lop/r), Remdesivir, Favipavir, acting over bacterial co-infection Azithromycin (Azithro), or modifying the inflammatory response of the host (Tocilizumab).'}",{'NCT04359095'},NCT04359095
1,,,"remdesivir, favipavir",FALSE,1,FALSE,FALSE,"Treatments have been administered to patients with COVID-19 in order to control viral infection, among them: Chloroquine (CQ) and Hydroxychloroquine (HCQ), Lopinavir/Ritonavir (Lop/r), Remdesivir, Favipavir, acting over bacterial co-infection Azithromycin (Azithro), or modifying the inflammatory response of the host (Tocilizumab).","{'Treatments have been administered to patients with COVID-19 in order to control viral infection, among them: Chloroquine (CQ) and Hydroxychloroquine (HCQ), Lopinavir/Ritonavir (Lop/r), Remdesivir, Favipavir, acting over bacterial co-infection Azithromycin (Azithro), or modifying the inflammatory response of the host (Tocilizumab).'}",{'NCT04359095'},NCT04359095
,1,,cq,FALSE,1,FALSE,FALSE,"Treatments have been administered to patients with COVID-19 in order to control viral infection, among them: Chloroquine (CQ) and Hydroxychloroquine (HCQ), Lopinavir/Ritonavir (Lop/r), Remdesivir, Favipavir, acting over bacterial co-infection Azithromycin (Azithro), or modifying the inflammatory response of the host (Tocilizumab).","{'Treatments have been administered to patients with COVID-19 in order to control viral infection, among them: Chloroquine (CQ) and Hydroxychloroquine (HCQ), Lopinavir/Ritonavir (Lop/r), Remdesivir, Favipavir, acting over bacterial co-infection Azithromycin (Azithro), or modifying the inflammatory response of the host (Tocilizumab).'}",{'NCT04359095'},NCT04359095
1,,,exparel,FALSE,1,FALSE,FALSE,Use of Liposomal Bupivacaine (Exparel) In Expedited Recovery Following Lower Extremity Amputation.,{'Use of Liposomal Bupivacaine (Exparel) In Expedited Recovery Following Lower Extremity Amputation.'},{'NCT04360421'},NCT04360421
,,1,contrast,FALSE,1,FALSE,FALSE,Virtual Histology of the Bladder Wall for Bladder Cancer Staging; A Novel Intravesical Contrast-Enhanced MRI for Bladder Cancer Staging.,{'Virtual Histology of the Bladder Wall for Bladder Cancer Staging; A Novel Intravesical Contrast-Enhanced MRI for Bladder Cancer Staging.'},{'NCT04369560'},NCT04369560
1,,,deltarex-g,FALSE,1,FALSE,FALSE,"When injected intravenously, the DeltaRex-G nanoparticles has a navigational system that targets exposed collagenous proteins (XC proteins) in injured tissues (e.g. inflamed lung, kidney, etc.), thus increasing the effective drug concentration at the sites of injury, in the vicinity of activated/proliferative T cells evoked by COVID-19.","{'When injected intravenously, the DeltaRex-G nanoparticles has a navigational system that targets exposed collagenous proteins (XC proteins) in injured tissues (e.g. inflamed lung, kidney, etc.), thus increasing the effective drug concentration at the sites of injury, in the vicinity of activated/proliferative T cells evoked by COVID-19.', 'DeltaRex-G nanoparticles (~100 nm) can mimic RNA virus SARS-CoV-2 by binding to viral receptors in human cells and may serve as a decoy to prevent SARSCoV-2 cell entry by crowding/neutralizing the SARS-CoV-2 even where the receptors may be different.', 'Intravenous DeltaRex-G has minimal systemic toxicity due to its navigational system (targeting properties) that limits the biodistribution of DeltaRex-G only to areas of injury where exposed collagenous (XC) proteins are abnormally found; and 4.', 'DeltaRex-G is currently available in FDA approved ""Right to Try"" or Expanded Access Program for Stage 4 cancers for an intermediate size population.', 'To gain this approval, FDA requires DeltaRex-G to have demonstrated safety and efficacy in early clinical trials'}",{'NCT04378244'},NCT04378244
68,40,15,,,,,,,,,